Launched following USFDA approval, this product is the therapeutically equivalent to Osmotica Pharmaceutical US LLC’s Venlafaxine Extended-Release Tablets, 150mg and 225mg.
Pharma major Dr Reddy’s Laboratories has launched Venlafaxine ER tablets in the US market.
Launched following US Food and Drug Administration (USFDA) approval, the product is clinically equivalent to Osmotica Pharmaceutical US LLC’s Venlafaxine Extended-Release Tablets, 150mg and 225mg. A selective serotonin and norepinephrine reuptake inhibitor (SNRI), venlafaxine extended-release tablets are indicated for major depressive disorder (MDD) and social anxiety disorder (SAD).
Dr Reddy’s said in a release, citing IQVIA Health numbers, that the brand and generic had sales of approximately $51 million MAT in the US for the most recent 12 months ending October 2021. Venlafaxine ER tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90, the company said.
,